Gastrointestinal Drugs Advisory Committee; Cancellation, 23426 [E9-11725]
Download as PDF
<![CDATA[
23426
Federal Register / Vol. 74, No. 95 / Tuesday, May 19, 2009 / Notices
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20852. (301) 435–
6033. rajarams@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel, Hemorrhage Trial.
Date: June 10, 2009.
Time: 4 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852. (Telephone
Conference Call.)
Contact Person: Richard D. Crosland, PhD,
Scientific Review Administrator, Scientific
Review Branch, Division of Extramural
Research, NINDS/NIH/DHHS/Neuroscience
Center, 6001 Executive Blvd., Suite 3208,
MSC 9529, Bethesda, MD 20892–9529. 301–
594–0635. rc218u@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Time: 11 a.m. to 12:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6120
Executive Blvd., Rockville, MD 20852.
(Telephone Conference Call).
Contact Person: Sheo Singh, PhD,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
Executive Plaza South, Room 400C, 6120
Executive Blvd., Bethesda, MD 20892. 301–
496–8683. singhs@nidcd.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: May 12, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–11584 Filed 5–18–09; 8:45 am]
Food and Drug Administration
Dated: May 11, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–11480 Filed 5–18–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Docket No. FDA–2009–N–0664]
BILLING CODE 4140–01–P
Gastrointestinal Drugs Advisory
Committee; Cancellation
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
HHS.
AGENCY:
ACTION:
Food and Drug Administration,
Notice.
National Institutes of Health
mstockstill on PROD1PC66 with NOTICES
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders. Special Emphasis Panel. RFP
Auditory Nerve.
Date: June 4, 2009.
VerDate Nov<24>2008
16:48 May 18, 2009
Jkt 217001
SUMMARY: The meeting of the
Gastrointestinal Drugs Advisory
Committee scheduled for May 20, 2009,
is cancelled. This meeting was
announced in the Federal Register of
April 7, 2009 (74 FR 15739). The FDA’s
Center for Drug Evaluation and Research
is continuing to review the application
that was going to be discussed by the
committee.
FOR FURTHER INFORMATION CONTACT:
Kristine T. Khuc, Center for Drug
Evaluation and Research (HFD–21),
Food and Drug Administration, 5630
Fishers Lane (for express delivery, 5630
Fishers Lane, rm. 1093), Rockville, MD
20857, 301–827–7001, FAX: 301–827–
6776, e-mail:
Kristine.Khuc@fda.hhs.gov, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code
3014512538. Please call the Information
Line for up-to-date information on this
meeting.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
Dated: May 14, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9–11725 Filed 5–15–09; 4:15 pm]
BILLING CODE 4160–01–S
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–5281–N–35]
Supplement to Application for
Federally Assisted Housing
AGENCY: Office of the Chief Information
Officer, HUD.
ACTION: Notice.
SUMMARY: The proposed information
collection requirement described below
has been submitted to the Office of
Management and Budget (OMB) for
review, as required by the Paperwork
Reduction Act. The Department is
soliciting public comments on the
subject proposal.
Section 644 of the Housing and
Community Development Act of 1992
(42 U.S.C. 13604) imposed on HUD the
obligation to require housing providers
participating in HUD’s assisted housing
programs to provide any individual or
family applying for occupancy in HUDassisted housing with the option to
include in the application for
occupancy the name, address, telephone
number, and other relevant information
of a family member, friend, or person
associated with a social, health,
advocacy, or similar organization. The
objective of providing such information,
if this information is provided, and if
the applicant becomes a tenant, is to
facilitate contact by the housing
provider with the person or organization
identified by the tenant, to assist in
providing the delivery of any services or
special care to the tenant and assist with
resolving any tenancy issues arising
during the tenancy of such tenant. This
supplemental application information is
to be maintained by the housing
provider and maintained as confidential
information.
DATES: Comments Due Date: June 18,
2009.
ADDRESSES: Interested persons are
invited to submit comments regarding
this proposal. Comments should refer to
the proposal by name and/or OMB
approval Number (2502–Pend) and
should be sent to: HUD Desk Officer,
Office of Management and Budget, New
Executive Office Building, Washington,
DC 20503; fax: 202–395–6974.
FOR FURTHER INFORMATION CONTACT:
Lillian Deitzer, Reports Management
E:\FR\FM\19MYN1.SGM
19MYN1
]]>Agencies
[Federal Register Volume 74, Number 95 (Tuesday, May 19, 2009)]
[Notices]
[Page 23426]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-11725]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0664]
Gastrointestinal Drugs Advisory Committee; Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Gastrointestinal Drugs Advisory Committee
scheduled for May 20, 2009, is cancelled. This meeting was announced in
the Federal Register of April 7, 2009 (74 FR 15739). The FDA's Center
for Drug Evaluation and Research is continuing to review the
application that was going to be discussed by the committee.
FOR FURTHER INFORMATION CONTACT: Kristine T. Khuc, Center for Drug
Evaluation and Research (HFD-21), Food and Drug Administration, 5630
Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093),
Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail:
Kristine.Khuc@fda.hhs.gov, or FDA Advisory Committee Information Line,
1-800-741-8138 (301-443-0572 in the Washington, DC area), code
3014512538. Please call the Information Line for up-to-date information
on this meeting.
Dated: May 14, 2009.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E9-11725 Filed 5-15-09; 4:15 pm]
BILLING CODE 4160-01-S
